"Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” - WSJ
• Thin on details and given that the industry has so far committed $350bn of investment into the US (WSJ numbers) most companies should have a get-out here.
• Of course, we don't know what the hurdle would be to avoid tariffs.
• Sandoz is most exposed here as Generics are key to their business.
• Sandoz in Q1 reported only ONE US manufacturing site out of a total of 15. The US site is dedicated to serving US customers with North America representing 21% of sales.
Find more articles and bullets on these widgets:
The primary trend condition in BTP futures is unchanged, the direction remains up. However, for now, the contract continues to trade inside a range and the Aug 15 sell-off signals scope for a move towards the lower end of the range. Key support to watch lies at 119.59, the Jul 25 low. A clear break of this level would highlight a range breakout and a bearish threat. Key resistance is unchanged at 121.73, the Jun 13 high.
A bear cycle in Gilt futures remains in play and yesterday’s fresh cycle low reinforces current conditions. Note that on the continuation chart, moving average studies are in a bear-mode position, highlighting a clear downtrend - for now. First support to watch is 90.25, the Aug 26 low. A break would resume the bear leg and open the 90.00 handle. Initial resistance is at 91.24, the Aug 18 high.